Jerini Reports Financial Results for First Nine Months of 2007

Berlin, November 14, 2007 - Jerini AG (FSE:JI4) reported financial results according to International Financial Reporting Standards (IFRS) for the first nine months ended September 30, 2007. Total revenues for the nine-month period ended September 30, 2007, increased by 70.8 percent to ¤ 16.2 million (prior year period: ¤ 9.5 million). Revenues from collaboration agreements increased to ¤ 13.0 million (prior year period: ¤ 7.0 million), mainly due to a payment from Abbott in accordance with an agreement concluded on September 4, 2007, in which Jerini regained the worldwide rights to Icatibant for the treatment of hereditary angioedema (HAE). Cash and cash equivalents as of September 30, 2007, amounted to ¤ 50.6 million. "Jerini has made significant progress in the last year. The completion of US and EU regulatory filings for Icatibant in HAE along with the start of clinical testing in age-related macular degeneration have brought the company to a new level in its development," said Jens Schneider-Mergener, CEO of Jerini. "We are now in a very strong position to realize our goal of launching Icatibant for the treatment of HAE in 2008." Research and development expenses increased in the first nine months of 2007 to ¤ 20.3 million (prior year period: ¤ 17.4 million) as a result of a milestone payment to sanofi-aventis. General and administrative expenses increased to ¤ 7.0 million (prior year period: ¤ 5.7 million), mainly attributable to the hiring of new employees. Marketing and sales expenses increased to ¤ 4.8 million (prior year period: ¤ 3.4 million) mainly due to intensified preparations undertaken by Jerini US, Inc. for the planned market launch of Icatibant in 2008. Loss from operations before tax and finance cost (EBIT) decreased to ¤ 17.2 million (prior year period: ¤ 18.4 million). Net loss for the nine-month period ended September 30, 2007 amounted to ¤ 15.5 million (¤ 16.7 million for the first nine months of 2006). Loss per share for this period amounted to ¤ 0.29 (prior year period: ¤ 0.32). Net cash burn for the first nine months of 2007 amounted to ¤ 15.4 million (prior year period: ¤ 21.5 million). Net cash burn is calculated by the addition of cash used in operating activities (¤ 14.6 million) and cash used in investing activities (¤ 0.8 million), as disclosed in the unaudited consolidated cash-flow statements for the nine-month period ended September 30, 2007. Outlook Having regained worldwide marketing rights to Icatibant, Jerini plans to launch Icatibant with its own sales and marketing teams in both the US and Europe. Launch preparations for both regions are running in parallel, with the current emphasis on implementing pre-marketing programs, which include working with patient organizations, key opinion leaders, and HAE-treating physicians to raise awareness of Icatibant, HAE, and bradykinin as its key mediator. Led by Jerini's commercial directors and key account managers, the company is conducting market research, participating in national and international medical conferences, targeting publications in scientific media, and attending national patient meetings. The commercial teams will also work closely with national reimbursement authorities to ensure Icatibant's full reimbursement following approval. Jerini also has manufacturing and logistic plans in place to ensure rapid product distribution following product launch. Jerini Ophthalmic, Inc. continues to enroll patients in its Phase I clinical trial evaluating JSM 6427 for the treatment of age-related macular degeneration. The company expects the trial to be completed in 2008. Management projects a cash burn for the year of approximately ¤ 32 million, which is lower than previous guidance due to a payment from Abbott and revised timing of clinical programs. Clinical development expenses, market launch preparations, and further development of other preclinical programs are the main factors behind cash burn and spending in 2007 and 2006. About Jerini AG Jerini is a pharmaceutical company based in Berlin, Germany, focusing on the discovery, development, and commercialization of novel peptide-based drugs. The company pursues disease indications that have limited or no treatment options and has built a drug pipeline composed of its own programs, as well as others in collaboration with established partners. Jerini has completed Phase III clinical trials of Icatibant in the subcutaneous treatment of hereditary angioedema (HAE). In August 2007, the company's Marketing Authorization Application (MAA) was accepted for review by the European Medicines Evaluation Agency (EMEA) and granted accelerated assessment by the agency, shortening the regulatory review period from 210 to 150 calendar days. In October 2007, Jerini filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) and requested priority review. Based on its technology platform, Jerini has also established several in-house development programs, which address indications within the therapeutic areas of ophthalmology, oncology, and inflammatory disease. ISIN: DE0006787476 For questions, please contact: Stacy Wiedenmann Director Investor Relations & Corporate Communications Jerini AG Invalidenstr. 130 10115 Berlin T + 49 - 30 - 97893 - 285 X + 49 - 30 - 97893 - 105